An evaluation of the molecular species of CA125 across the three phases of the menstrual cycle
CA125, a tumor-associated antigen, is primarily used to monitor epithelial ovarian cancer. However, CA125 alone lacks the sensitivity and specificity necessary for population-based screening in healthy women. Barriers to the development of a screening assay includes the low incidence of the disease, large inter-individual variability in CA125 levels, fluctuations in levels during the phases of the menstrual cycle (i.e., menses, follicular, luteal), ethnicity, menopausal status, and other benign conditions
Thesis, Dissertation, English, 2010
Dissertation Abstracts International
2010